JPMorgan Chase & Co. Issues Positive Forecast for Protagonist Therapeutics (NASDAQ:PTGX) Stock Price
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target upped by analysts at JPMorgan Chase & Co. from $53.00 to $57.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside […]
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target upped by analysts at JPMorgan Chase & Co. from $53.00 to $57.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside […]
